This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Day, C. Articles by Bailey, C. J Search for Related Content Social Bookmarking                         What's this?

Sibutramine update

Diabetes Group, Pharmaceutical Sciences, Aston University, Birmingham, B4 7ET, UK, cday{at}mededuk.com

Clifford J Bailey

The introduction of sibutramine has brought a new therapeutic option for the management of many overweight and obese patients. To date it has been used by more than eight million patients in over 70 countries. As part of a comprehensive programme that includes diet and lifestyle guidance, the additive effect of sibutramine (10 or 15 mg/day) facilitates patients to achieve and sustain greater weight loss. Overall weight loss is typically 5—10% of starting body weight, and this is almost entirely due to loss of excess adipose tissue. Commensurate with this level of weight loss, benefits have been noted in comorbidities such as insulin resistance, type 2 diabetes and dyslipidaemia. Sibutramine is a serotonin-noradrenaline (norepinephrine) re-uptake inhibitor which acts centrally to induce satiety and maintain thermogenic expenditure. The main side effects are increased heart rate and blood pressure which are generally small, but require frequent checks.

Key Words: sibutramine • obesity • overweight • seratonin noradrenaline re-uptake inhibitors • SNRI.

References

• Kopelman PG Obesity as a medical problem. Nature 2000;404:635-43.[Web of Science][Medline] [Order article via Infotrieve]
• James WP, Finer N. The role of sibutramine in weight management. Int J Obesity 2001;25(suppl 4):S34-38.[Web of Science]
• Lean MEJ. Sibutramine: a review of clinical efficacy. Int J Obesity 1997; 21(suppl 1):S30-36.
• Bray GA, Blackburn GL, Ferguson GM et al. Sibutramine produces dose-related weight loss. Obes Res 1999;7:189-98.[Web of Science][Medline] [Order article via Infotrieve]
• Cuellare GE, Ruiz AM, Mousalve MC, Barber A. Six-month treatment of obesity with sibutramine 15 mg: a double-blind, placebo controlled monocenter clinical trial in a Hispanic population. Obesity Res 2000; 8:71-82.[Web of Science][Medline] [Order article via Infotrieve]
• Finer N. Sibutramine in clinical practice. Int J Obesity 2001;25(suppl 4): S12-15.[Web of Science]
• Smith IG, Goulder MA Randomised placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001;50:505-12.[Web of Science][Medline] [Order article via Infotrieve]
• Hansen D., Astrup A., Toubro S. et al. Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Int J Obesity 2001;25:496-501.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Apfelbaum M., Vague P., Ziegler O. et al. Long-term maintenance of weight loss after a very-low-calorie diet: a randomised blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999;106:179-84.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• James WPT, Astrup A., Finer N. et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 2000;356: 2119-25.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Wirth A., Krause J. Long-term weight loss with sibutramine. A randomised controlled trial. JAMA 2001;286:1331-9.[Abstract/Free Full Text]
• Gokcel A., Gumurdulu Y., Karakose H. et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obesity Metab 2002;4:49-55.[CrossRef]
• Wadden TA, Berkowitz RI, Womble LG et al. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obesity Res 2000;8:431-7.[Web of Science][Medline] [Order article via Infotrieve]
• Lean MEJ. The role of central fat accumulation in type 2 diabetes. Br J Diabetes Vasc Dis 2001;1:115-17.[Abstract/Free Full Text]
• Kamel EG, McNeill G., Van Wijk MC Change in intra-abdominal adipose tissue volume during weight loss in obese men and women: correlation between magnetic resonance imaging and anthropometric measurements. Int J Obesity 2000;24:607-13.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Finer N., Bloom SR, Frost GS et al. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blinded, placebo-controlled study. Diabetes Obesity Metab 2000;2: 105-12.[CrossRef]
• Scheen AJ, Lefebvre PJ Antiobesity pharmacotherapy in the management of type 2 diabetes. Diabetes Metabol Res Rev 2000;16:114-24.[CrossRef]
• McNeely W., Goa KL Sibutramine. A review of its contribution to the management of obesity. Drugs 1998;56:1093-124.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Fujioka K., Seaton TB, Rowe E. et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obesity Metab 2000;2: 175-87.[CrossRef]
• Gokcel A., Karakose H., Ertorer EM et al. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care 2001;24:1957-60.[Abstract/Free Full Text]
• Serrano-Rios M., Melchionda N., Moreno-Carretero E. Role of sibutramine in the treatment of obese type 2 diabetic patients receiving sulphonylurea therapy. Diabetic Med 2002;19:119-24.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Bailey CJ, Turner SL, Bates SH, Jones RB Sibutramine metabolites increase glucose transport by cultured rat muscle cells. Int J Obesity 2001;25:478-85.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Dujovne CA, Zavirak JH, Rowe E. et al. Effects of sibutramine on body weight and serum lipids: a double blind, randomised, placebo-controlled study in 322 overweight and obese patients with dyslipidaemia. Am Heart J 2001;142:489-97.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Sharma AM Sibutramine in overweight/obese hypertensive patients. Int J Obesity 2001;25(suppl 4):S20-23.[Web of Science]
• Hazenburg BP Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. Cardiology 2000;94:152-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• McMahon FG, Fujioka K., Singh BN et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Int Med 2000;160:2185-91.[Abstract/Free Full Text]
• Faria AN, Ribeiro Filho FF, Lerarlo DD et al. Effects of sibutramine on the treatment of obesity in patients with arterial hypertension. Arq Bras Cardiol 2002;78:172-80.[Medline] [Order article via Infotrieve]
• McMahon FG, Weinstein SP, Rowe E. et al. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 2002;16:5-11.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Sramek JJ, Leibowitz MT, Weinstein SP et al. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. J Hum Hypertens 2002;16:13-19.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Stock MJ Sibutramine: a review of the pharmacology of a novel antiobesity agent. Int J Obesity 1997;21(suppl 1):S25-29.[Web of Science]
• Heal DJ, Aspley S., Prow MR et al. Sibutramine: a novel anti-obesity drug. Int J Obesity 1998;22(suppl 1):S18-28.[Web of Science]
• Jackson HC, Bearham MC, Hutchins LJ et al. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br J Pharmacol 1997;121: 1613-18.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Rolls BJ, Shide DJ, Thorwatt ML et al. Sibutramine reduces food intake in non-dieting women with obesity. Obesity Res 1998;6:1-11.[Web of Science][Medline] [Order article via Infotrieve]
• Schuh LM, Schuster CR, Hopper JA, Mendel CM Abuse liability assessment of sibutramine, a novel weight control agent. Psychopharmacology 2000;147:339-46.[CrossRef][Medline] [Order article via Infotrieve]
• Hanson DL, Toubro S., Stock et al. Thermogenic effects of sibutramine in humans. Am J Clin Nutr 1998;68:1180-6.[Abstract]
• Hansen DL, Toubro S., Stock MJ et al. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obesity 1999;23:1016-24.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Walsh KM, Leen E., Lean MJ The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females. Int J Obesity 1999;23:1009-15.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Berube-parent S., Prud'homme D., St-Pierre S. et al. Obesity treatment with a progressive clinical tri-therapy combining sibutramine and a supervised diet-exercise intervention. Int J Obesity 2001;25:1144-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Appolinario JC, Godoy-Matos A., Fontenelle LF et al. An open-label trial of sibutramine in obese patients with binge-eating disorder. J Clin Psychiatry 2002;63:28-30.[Web of Science][Medline] [Order article via Infotrieve]
• Samsa GP, Kolotkin RL, Williams GR et al. Effect of moderate weight loss on health-related quality of life: analysis of combined data from 4 randomised trials of sibutramine versus placebo. Am J Manag Care 2001;7: 926-7.[Web of Science][Medline] [Order article via Infotrieve]
• Bach DS, Rissanen AM, Mendel CM et al. Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obesity Res 1999;7:363-9.[Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 2, No. 5, 392-397 (2002)
DOI: 10.1177/14746514020020050901


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Day Diagnostic definitions -- metabolic syndrome The British Journal of Diabetes & Vascular Disease, May 1, 2005; 5(3): 115 - 118. [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Day, C. Articles by Bailey, C. J Search for Related Content Social Bookmarking                         What's this?